Ubiquitome’s Liberty16 Attracts Swiss Giant
Swiss giant DKSH signs agreement to market Ubiquitome's mobile, battery powered, PCR COVID-19 fast tester, Liberty16, in the Asia-Pacific market as manufacturing is ramped up with NZ$578,000 backing from the NZ government. DKSH’s Singapore-based Business Unit Technology, will provide marketing and sales, and distribution and logistics as well as after-sales services for the Liberty16.
New Zealand’s Ubiquitome signs NIH RADx contract
New Zealand-based Ubiquitome is ramping up production of its mobile, real-time (RT) PCR technology with funding from the United States’ National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) initiative. Ubiquitome is the only NZ private company to be accepted into the highly competitive RADx and to receive federal funding through the NIH in recent years.
The Liberty16 has been designed to meet or exceed the performance of laboratory based real time PCR platforms.
“All established assays were shown to be transferable and gave comprehensible results .”
- The Institute of Environmental Science and Research (ESR)
SPECIFICATIONS FOR THE LIBERTY16
|Block Format||16 wells|
|Thermal system||Peltier-based system|
|Consumables||Industry standard 8 strip PCR tube and caps|
|Sample volume||10μl to 40μl|
|Average ramp rate||2.3°C/sec|
|Ambient operation||10°C – 40°C|
|Calibrated dyes||SYBR Green, FAM|
|Data collection||Data collected for all wells|
|Battery||Internal - rechargeable lithium ion|
|Outside dimensions||Length closed: 21.2 cm (8.35 inches)
Width: 11 cm (4.33 inches)
Height: 11.5 cm (4.53 inches)
|Weight||3.2 kg (7.05 lb)|
To help us understand your needs and provide the quickest response, please select one of the options below.